

UDK 577.21:616.34-006

Review article

Received: 17 March 2015

Accepted: 15. April 2015

MOLECULAR STRATIFICATION OF COLORECTAL CANCER

Sanja Kapitanović

Laboratory for Personalized Medicine, Division of Molecular Medicine
Ruđer Bošković Institute, Zagreb, Croatia

Summary

Colorectal cancer (CRC) is one of the most common cancers and one of the leading causes of cancer death in the Western world. The disease arises from the accumulation of mutations in oncogenes, tumor suppressor genes and mismatch repair genes during progression from normal colon epithelium to adenoma and metastatic carcinoma. Improved understanding of genetic events that underline tumor development and progression may contribute to new strategies for prevention, diagnosis as well as for therapy. The results of Human genome project showed that each person has its unique genetic “signature” as a consequence of a large number of inherited genetic variations. There are also sporadic molecular changes specific for each tumor type. This mini review will give some information about the most frequent molecular genetics changes in colorectal cancer and its molecular stratification due to its heredity, germline pharmacogenetic markers, somatic mutations and microsatellite instability.

Keywords: colorectal cancer; biomarkers; molecular stratification.

Colorectal cancer (CRC) is one of the most common cancers and represents the third most diagnosed cancer in both men and women. Despite advances in surgery, chemotherapy and screening it is still one of the leading causes of cancer related death in the Western world [1].

Of all human cancers, the molecular genetic alterations in colorectal cancer are best understood. The disease arises from the accumulation of mutations in oncogenes, tumor suppressor genes and mismatch repair (MMR) genes during progression from normal colon epithelium to adenoma and metastatic carcinoma (Figure 1) [2].




Figure 1. Multistep model of colorectal cancer tumorigenesis.

The majority of colon cancers (80%) arise in sporadic form and only 20% of the patients have a family history of CRC. However, only 5-6% of CRC arise from a germline mutation in high penetrant genes, adenomatous polyposis coli (APC) gene (1%) and MMR genes (5%) while the remaining CRCs have a positive family history but cannot be categorized to any hereditary CRC syndrome. These familial CRC are caused by single nucleotide polymorphisms (SNP) in less penetrant genes such as cytokines. Many susceptibility loci have been identified, however, their value in CRC risk prediction remains low [3,4].

The development of colorectal cancer is a multistep process caused by progressive accumulation of genetic and epigenetic changes that cause activation of oncogenes and/or inactivation of tumor suppressor genes. The earliest trigger is the mutation of the APC (adenomatous polyposis coli) gene. Mutations in oncogenes (KRAS) and other tumor suppressor genes (p53, DPC4) drive tumor towards malignant transformation and metastasis. Alongside with gene mutations, deregulated expression of oncogenes and/or tumor suppressor genes can also occur as a consequence of epigenetic modifications of their promoters [3,5-7].

Improved understanding of genetic events that underline tumor development, progression and metastasis may contribute to new strategies for prevention, screening, diagnosis as well as for therapy. Survival of patients with metastatic colorectal cancer has improved over the past several decades, due to the development of new combinations of standard chemotherapy such as 5-fluorouracil (5-FU), irinotecan, and oxaliplatin, as well as to the introduction of new targeted therapies. Among the available targeted therapies are monoclonal antibodies that target the epidermal growth factor receptor (EGFR) which have clearly demonstrated efficacy in the treatment of metastatic CRC [8,9].

Individual patient response to therapy could be very diverse, even if their disease seems similar when evaluating clinicopathological parameters. Many drugs commonly used in clinical practice show interindividual variations in efficacy, dose requirements as well as the presence of side effects. There is increasing evidence that treatment response is based on the genetic “signature” of the individuals as well as on the molecular changes in the tumor itself. Pharmacogenetics is the field of personalized medicine that examines the impact of genetic variations on the individual response to drug treatment. These variations are often due to germ line mutations in genes that encode for drug metabolizing enzymes, transporters, cellular targets and signaling pathway. For example, patients with variant DPYD*2A in dihydropyrimidine dehydrogenase (DPD) gene are at high risk to develop severe 5-FU toxicity as well as patients with a variant UGT1A1*28 in uridine diphosphat-glucuronosyl transferase 1A1 (UGT1A1) gene are at a higher risk of developing neutropenia and diarrhea when treated with irinotecan for CRC. Knowledge about the influence of these variations on drug response can be used to identify, through pretreatment genetic screening, the patients who will be responders to a specific drug and those at greater risk to develop an adverse drug reaction [10-13].

An important distinction between pharmacogenetics in oncology and other therapeutics fields is that somatic mutations, frequently acquired in cancer tissues, also contribute to the variations in treatment outcome, sensitivity or resistance to cancer therapy [13,14].

The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in normal cells as well as in tumorigenesis. EGFR also represents an important target for cancer treatment because its activation stimulates key processes involved in tumor growth and progression, including proliferation, angiogenesis, invasion, metastasis, and drug sensitivity (Figure 2) [8,15,16].




Figure 2. Epidermal growth factor receptor (EGFR) signaling pathway.

Novel therapeutic agents, anti-EGFR monoclonal antibodies, have been shown to be effective therapies for patients with metastatic CRC, but only in a small proportion of patients [15]. Alterations within the EGFR signaling cascade, such as gene mutations in its downstream regulators, have been shown to contribute to colorectal carcinogenesis, but are also predictive biomarkers of anti-EGFR therapy. Genetic analyses showed that the presence of somatic mutations in the KRAS, found in 40-60% of CRC, can predict lack of response and resistance to anti-EGFR antibodies in patients with metastatic CRC [16].

KRAS mutations, most commonly codon 12/13 missense mutations, lead to constitutive activation of the KRAS protein. Because KRAS is the downstream effector of EGFR, activating mutations in the KRAS gene lead to an independent activation of the downstream signal transduction. This unregulated downstream signaling will not be blocked by antibodies that target the EGFR receptor and KRAS mutation status is a strong predictive marker of resistance to EGFR targeted therapy [17]. Un-

fortunately at least 60% of patients with wild type KRAS gene will still not respond to anti-EGFR therapies, suggesting the need for additional biomarkers to help distinguished responders from no responders [17,18]

The BRAF gene encodes a serine-threonine protein kinase that is downstream of KRAS in the MAPK signaling pathway and mutations in these two genes are mutually exclusive. BRAF mutations occur in 5-22% of all colorectal cancers, and in 40-52% of CRC with microsatellite instability [19,20]. Analysis for mutations in both genes could identify as many as 40% of patients who have no chance of responding to this class of drugs. Retrospective studies suggest that concomitant detection of KRAS and BRAF mutations, combined with detection of mutations in two other genes (PIK3CA and PTEN), can identify up to 70% of patients who are unlikely to respond to anti-EGFR therapies [18].

Lynch syndrome (LS) is a dominantly inherited cancer syndrome in which predisposition to colorectal, endometrial, gastric and other cancers occurs due to the mutations in MMR genes. Mismatch repair proteins form a complex that detects and corrects replication errors. A deregulated MMR system due to the mutations in MMR genes leads to accelerated accumulation of somatic mutations, often resulting in carcinogenesis. The most frequently mutated MMR genes are MSH2 and MLH1, in 70-90% of Lynch syndrome, with the remaining 10-30% distributed equally in MSH6 and PMS2 [21].

Microsatellite instability (MSI) is the molecular marker of MMR genes mutations and DNA mismatch repair deficiency. Since its initial description in hereditary colorectal cancer in 1993 and its association with Lynch syndrome, the most common inherited cancer predisposition syndrome, new results suggests that MSI status may also be of prognostic and predictive biomarker in the management of sporadic CRC. To examine the presence of MSI in a CRC tumor the National Cancer Institute (NCI) workshop (1997) recommended to analyze a panel of five microsatellites including two mononucleotide (BAT25, BAT26) and three dinucleotide markers (D2S123, D5S346 and D17S250), (Figure 3), [22,23]. Depending on the number of microsatellite markers displaying additional alleles, MSI can be rated as MSI-high (MSI-H, >2 out of 5 markers), MSI-low (MSI-L, 1 out of 5), or microsatellite stable (MSS, 0 out of 5). MSI-H status could be finding in the most cases of LS colorectal tumors but also in 15% of sporadic CRC [24]. Most of these tumors also exhibit loss of MLH1 protein expression as a consequence of the epigenetic silencing of MLH1 gene promoter. Recent findings demonstrated that inactivation of the MMR system with MSI-H status and MLH1 protein negative tumors in hereditary as well as in sporadic CRC tumors can result in resistance to 5-FU treatment and could be used as valuable pharmacogenetic marker [25].




Figure 3. Analysis of microsatellite instability (MSI-high tumor). A. Blood; B. Normal tissue adjacent to tumor; C. Tumor tissue.

Clinicians have long known that each patient and their disease are unique. Recent advances in molecular medicine have enabled a more detailed understanding of the impact of genetics in disease development and progression. Each individual cancer as well as colorectal cancer has a set of molecular alterations that can be defined as the genetic “signature” of that particular tumor. Recent genomic analyses of different human tumors confirmed that individual tumors exhibit heterogeneous patterns of somatic mutations, gene amplifications and deletions, epigenetic profiles, and gene expression profiles. Modern molecular platforms give the ability to characterize tumors at multiple levels and to define biological subtypes of cancer. Cancers could be divided into subtypes that are more or less aggressive. Identification of a more aggressive subtype may influence the type of their treatment. Molecular stratification and sub classification of tumors will add a step to traditional clinical practice and better diagnosis and therapy of different types of cancer as well as colorectal cancer [26,27].

As more biomarkers will be identified and validated predicting testing will be used more extensively in clinical decision making. Optimization of tools to predict the risk for developing cancer, to diagnose a disease at an early stage, to give a prognosis, and predict treatment response is of great importance to the patients as well as to the health professionals.

References

- [1] Kinzler, KW, Vogelstein B. Lessons from hereditary colorectal cancer. *Cell*. 1996; 87: 159-70.
- [2] Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med*. 2004; 10: 789-99. doi:10.1038/nm1087
- [3] Migliore L, Migheli F, Spisni R, Coppede F. Genetics, cytogenetics and epigenetics of colorectal cancer. *J Biomed Biotech*. 2011; Article ID 792362. doi:10.1155/2011/792362
- [4] Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. *Gastroenterology*. 2010; 138: 2044-58. doi: 10.1053/j.gastro.2010.01.054.
- [5] Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell*. 1990; 61: 759-767.
- [6] Berg M, Soreide K. Genetic and epigenetic traits as biomarkers in colorectal cancer. *Int J Mol Sci*. 2011; 12: 9426-39. doi:10.3390/ijms12129426
- [7] Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. *Gut*. 2011; 60: 116-29. doi: 10.1136/gut.2009.206250.
- [8] Tol J, Punt CJA. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. *Clin Therapeut*. 2010; 32: 437-53. doi: 10.1016/j.clinthera.2010.03.012.
- [9] Wang HL, Lopategui J, Amin MB, Patterson SD. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. *Adv Anat Pathol*. 2010; 17: 23-32. doi: 10.1097/PAP.0b013e3181c6962f.
- [10] Roses AD. Pharmacogenetics and the practice of medicine. *Nature*. 2000; 405: 857-65.
- [11] Yalcin S. The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. *Gastrointest Cancer Res*. 2009; 3: 197-203. doi:10.1038/35015728
- [12] Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. *Br J Clin Pharmacol*. 2006; 62:35-46. doi: 10.1111/j.1365-2125.2006.02591.x
- [13] Esplin ED, Snyder MP. Genomic era diagnosis and management of hereditary and sporadic colon cancer. *World J Clin Oncol*. 2014; 5:1036-47. doi: 10.5306/wjco.v5.i5.1036
- [14] De Palma M, Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. *Mol Oncol*. 2012; 6:111-27. doi: 10.1016/j.molonc.2012.01.011
- [15] Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. *JNCI*. 2009; 101: 1308-12. doi: 10.1093/jnci/djp280.

- [16] Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. *Cancer Treatment Rev.* 2009; 35: 262-71. doi: 10.1016/j.ctrv.2008.11.005.
- [17] Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au H-J, Langer C, Moore MJ, Zalberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med.* 2008; 359: 1757-65. DOI: 10.1056/NEJMoa0804385
- [18] Pappou EP, Ahuja N. The role of oncogenes in gastrointestinal cancer. *Gastrointest Cancer Res: GCR.* 2010; Suppl 1: S2-S15.
- [19] Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. *Cancer Cell.* 2004; 6: 313-9. doi: 10.1016/j.ccr.2004.09.022
- [20] Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. RAF/RAS oncogenes and mismatch-repair status. *Nature.* 2002; 418: article 934. doi: 10.1038/418934a
- [21] Cohen SA, Leininger A. The genetic basis of Lynch syndrome and its implications for clinical practice and risk management. *Appl Clin Genet.* 2014; 7:147-58. doi: 10.2147/TACG.S51483.
- [22] Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshelman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* 1998; 58:5248-57.
- [23] Umar A, Boland CR, Terdiman JP, Syngal S, de Chapelle A, Rushoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst.* 2004; 96:261-8. doi: 10.1093/jnci/djh034
- [24] Heinemann K. Toward a molecular classification of colorectal cancer: the role of microsatellite instability status. *Frontiers Oncol.* 2013; 3:272. doi:10.3389/fonc.2013.00272
- [25] Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola RM, Bujanda L, Reñé JM, Clofent J, Bessa X, Morillas JD, Nicolás-Pérez D, Pons E, Payá A, Alenda C; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. *Eur J Cancer.* 2009; 2:365-73. Doi:10.1016/j.ejca.2008.07.016

- [26] Tan P. Divide and conquer: progress in the molecular stratification of cancer. *Yonsei Med J.* 2009; 50:464-473. doi: 10.3349/ymj.2009.50.4.464
- [27] Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes. Implications of the unique tumor principle in personalized medicine. *Expert Rev Mol Diagn.* 2012; 12:621-628. doi: 10.1586/erm.12.46.

Sažetak

Molekularna stratifikacija kolorektalnog raka

Kolorektalni karcinom je jedan od najčešćih zloćudnih tumora i jedan od vodećih uzroka smrti od raka u zemljama razvijenog svijeta. Oboljenje nastaje kroz duži niz godina tijekom kojih kao posljedica mutacija u onkogenima, tumor supresorskim genima i genima za popravak DNA iz normalne sluznice kolona preko adenoma nastaje zloćudni invazivni karcinom. Dobro poznavanje molekularne podloge nastanka i napredovanja kolorektalnog karcinoma doprinosi boljoj prevenciji, ranoj dijagnostici i uspješnijoj terapiji ovog zloćudnog tumora. Rezultati istraživanja u području molekularne patologije raka ukazuju na to da svaki tumor posjeduje svoj vlastiti genetski otisak koji je rezultat individualnih, za taj tumor specifičnih, molekularnih promjena ali i genetičkih karakteristika oboljele osobe. U ovom kratkom preglednom radu opisane su najčešće molekularno genetičke promjene u kolorektalnom karcinomu te molekularna stratifikacija ovog zloćudnog tumora s obzirom na nasljednost, farmakogenetske biljege, stečene mutacije i mikrosatelitnu nestabilnost.

Ključne riječi: kolorektalni rak; biomarkeri; molekularna stratifikacija.

Corresponding author:
Sanja Kapitanović
E-mail: kapitan@irb.hr